NCT03550482 - Oncoxin® and Quality of Life in Cancer Patients | Biotech Hunter

Enrollment

133

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

March 15, 2019

Study Completion Date

May 15, 2019

Conditions

Gastric Cancer Stage IINon-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage IIIGastric Cancer Stage III

Interventions

DIETARY_SUPPLEMENT

ONCOXIN®

Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI \<20 and serum albumin levels \<30 g/l received nutritional support.

Trial Locations (9)

111123

State-funded Healthcare Institution Oncologic Clinical Dispensary No.1, Moscow

The Loginov Moscow Clinical Scientific Center, www.mknc.ru, Moscow

214025

"Non-government Healthcare Institution Hospital of JSC Russian Railways Hospital at the Station Smolensk", Smolensk

443001

"Medical University Reaviz", Samara

454048

"Medical Center EVIMED LLC", Chelyabinsk

628012

State-funded Institution of Khanty-Mansiysk Regional Clinical Hospital, Ugra

628400

"State-funded Institution Surgut Regional Hospital", Surgut

Unknown

Kazakh Research Institute of Oncology and Radiology, Almaty

"State Municipal Enterprise on the Right of Economic Management Almaty Oncology Center of Almaty Healthcare Administration", Almaty

All Listed Sponsors

lead

Catalysis SL

INDUSTRY